BioMarin Completes Acquisition of Amicus Therapeutics
BioMarin completed the acquisition of Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion, or $14.50 per share. The deal adds Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease to BioMarin's commercial portfolio, along with U.S. rights to the Phase 3 asset DMX-200.
Key figures
- Guidance
- BioMarin Expects to Provide Updated FY 2026 Guidance During its First Quarter Earnings Call, May 4, 2026
- Deal Value Usd
- $4.8 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.